AX-2026-043395

CJC-1295 with DAC · 10 mg declared · WuXi TIDES (WuXi AppTec Testing Division) · lot WXT-2602-F3755

MARGINALVERIFIED

Report ID: AX-2026-043395
Compound: CJC-1295 with DAC
Compound class: Growth-hormone axis peptides
Supplier: WXT — WuXi TIDES (WuXi AppTec Testing Division)
Batch / lot: WXT-2602-F3755
Declared label claim: 10mg
Laboratory: Nordanalyt Laboratories
Assay date: 04 Jun 2026
Submitted: 09 Jun 2026
Quarter: 2026-Q2
Submitter: h.nakamura
Sample provenance: Supplier-supplied

Section 1

Results

Measured against the index acceptance specification for the growth-hormone axis peptides class. A specification is a decision the index made; a result is a measurement. See where each threshold came from.

Parameter	Method	Result	Unit	Index spec
Purity	RP-HPLC, 35 min gradient, 214 nm	98.24	% area	≥ 97.5	PASS
Total impurities	RP-HPLC, sum of reported peaks	1.76	% area	≤ 2.5	PASS
Largest single impurity	RP-HPLC — hydrolysed maleimide (+18 Da)	0.80	% area	≤ 1.00	PASS
Identity — theoretical monoisotopic mass	calculated from molecular formula	3644.9748	Da	—	NOT TESTED
Identity — observed monoisotopic mass	LC-MS, high resolution (ESI-TOF/QTOF)	3644.9894	Da	—	NOT TESTED
Mass accuracy	observed vs theoretical	+4.0	ppm	± 15	PASS
Total peptide content	by difference from the gravimetric mass balance	90.88	%w/w	—	NOT TESTED
Target-compound content	total peptide content × purity	89.28	%w/w	—	NOT TESTED
Gross fill (as weighed)	five-place balance, under nitrogen	10.04	mg	10 mg declared	NOT TESTED
Recovered target peptide	gross fill × target content	8.964	mg	10 mg claim	NOT TESTED
Recovery against label claim	recovered ÷ claim	89.6	%	90.0 – 110.0	FAIL
Water content	Karl Fischer, coulometric, duplicate	4.35	%	≤ 9.0	PASS
Counter-ion (acetate)	anion-exchange ion chromatography	4.15	%	≤ 12.0	PASS
Residual solvent + inorganic residue	estimated — see /methods/residual-solvents-q3c/	0.62	%	—	NOT TESTED
Endotoxin	not ordered on this submission	not determined	—	≤ 5.0	NOT TESTED
Sterility	not ordered on this submission	not determined	—	no growth	NOT TESTED
Appearance	visual, diffuse light, black and white background	White lyophilised cake, intact	—	white to off-white intact cake	PASS
Reconstitution clarity	reconstituted per submitter procedure	Visible particulates, did not clear	—	clear, no visible particulates	FAIL
pH (reconstituted, 1 mg/mL)	potentiometric, two-point calibration	4.02	—	2.5 – 8.0	PASS
Retention time (observed)	RP-HPLC, 35 min gradient	16.96	min	16.86 ± 0.35 (normalised)	PASS
Peak asymmetry (10 % height)	Ph. Eur. 2.2.46	1.30	—	0.80 – 1.50	PASS
Plate count, main peak	N = 5.54 (t/w½)²	59,175	—	≥ 20,000	PASS
Resolution to nearest impurity	vs deamidated (+1 Da)	1.06	—	no index criterion	REPORTED

Section 2

Chromatogram and peak integration

The figure is drawn from the table. It is not an independent illustration — if a number in the table changed, the trace would change with it.

Figure 1. RP-HPLC trace, 35 min gradient, 214 nm. Drawn from the peak-integration table below: peak positions are the reported retention times, peak areas are the reported area percentages, peak widths follow the reported plate count of 59,175, and skew follows the reported asymmetry factor of 1.30. Baseline noise is seeded from the report ID and is illustrative. The lower panel is the same trace at a stated vertical expansion with the slow gradient drift subtracted, because at full scale a 0.80 % impurity against a 98.24 % main peak is a line two pixels tall; the main peak runs off-scale there by design.

#	Peak	RT	Area (µV·s)	% area	Δ mass (Da)
1	CJC-1295 with DAC — main peak	16.96	4,774,769	98.24	—
2	hydrolysed maleimide (+18 Da)	16.24	38,882	0.80	+18.011
3	mod-GRF (1-29) (−279 Da)	14.91	28,676	0.59	-279.235
4	maleimide dimer	19.78	11,179	0.23	+3644.975
5	deamidated (+1 Da)	16.66	6,804	0.14	+0.984
Closure check — purity + Σ impurities				100.00	CLOSES

Reporting threshold 0.05 % area. Peaks below it are not reported and are therefore excluded from the total, which overstates purity by their sum — see peak integration.

Section 3

Mass spectrum and identity

Theoretical monoisotopic mass 3644.9748 Da, computed from C165H269N47O46. All ppm figures on this site are against monoisotopic values — see why that matters.

Figure 2. ESI charge-state envelope, high-resolution instrument. Sticks are placed at m/z = (M + z × 1.007276)/z for the observed neutral mass of 3644.9894 Da. Sodium (+21.982/z) and potassium (+37.956/z) adducts are shown where the parent charge state exceeds 25 % relative abundance; they are adducts of the same molecule and are not impurities.

Charge	Theoretical m/z	Observed m/z	Δ m/z	Rel. abundance (%)
5+	730.0022	730.0052	0.0030	7.9
4+	912.2510	912.2546	0.0036	53.1
3+	1215.9989	1216.0037	0.0048	100.0
2+	1823.4947	1823.5020	0.0073	53.0

Section 4

Gravimetric mass balance

Water, counter-ion, residual and total peptide content are exhaustive and mutually exclusive categories. They must account for 100 % of the cake mass. The index closes this to within 0.02 pp and the build asserts it.

Component	Determination	%w/w of cake
Water	Karl Fischer	4.35
Counter-ion (acetate)	ion chromatography	4.15
Residual solvent + inorganic residue	estimated	0.62
Total peptide content	by difference	90.88
Total		100.00 CLOSES

Supplier certificate, as declared

The supplier's own figures for this lot, beside the independent measurement. Divergence is assessed against the batch median, not against this single report — see rule AX-R05.

Figure	Supplier COA	This report	Index note
Purity (% area)	98.33	98.24	divergence +0.17 pp vs batch median
Total impurities (% area)	1.67	1.76
Largest single impurity (% area)	not stated	0.80
Water (%)	3.6	4.35
Counter-ion (%)	not stated	4.15
Peptide content (%w/w)	97.5	90.88
Endotoxin (EU/mg)	not stated	not determined
Method stated on certificate	NO	—	no method section — the result cannot be reconciled against any other

Section 5

Provenance and caveats

Where a sample came from changes the weight of the evidence. The index treats it as a first-class field.

Sample provenance: Supplier-supplied
Evidentiary weight: Weaker evidence. Read with the caveat below.
Chain of custody: Supplier despatch → laboratory direct (courier, cold pack, 3 d) → assay. Submitter did not handle the vial.
Assay date: 04 Jun 2026
Submitted to the index: 09 Jun 2026
Laboratory: Nordanalyt Laboratories, Uppsala, Sweden
Method basis: 35 min gradient · high-resolution MS
Verification status: VERIFIED

What this report does not establish

That the material is free of bacterial endotoxin. Endotoxin was not measured. No chromatographic result bears on it.
That the material is sterile. Sterility was not tested.
That any other vial in the same lot has the same composition. One vial was tested. Within-lot vial-to-vial variation in this index has a median of 0.28 pp and a 90th percentile of 0.74 pp.
That any other lot from the same supplier has the same composition. Batch-to-batch variation is larger than within-batch variation for every supplier here.
That the material is suitable for administration to a human or an animal. These are research compounds. No result on this site is a safety assessment and the index takes no position on use.
That the material was manufactured by the supplier that sold it. Contract synthesis is normal in this market and twenty-nine batches in the index fingerprint to a bulk from a different company than the one named on the label.

Section 6

Annotations

No annotations on this record. Annotations are short signed technical comments from index contributors; see how to contribute.

Section 7

Related records

Same batch — lot WXT-2602-F3755 n=2

Report	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043396	WXT-2602-F3755	Kestrel	2026-Q2	98.07	4.82	89.3	Supplier-supplied	2	MARGINAL

Batch rollup and reproducibility assessment →

Cross-sections

Other recent CJC-1295 with DAC records in the index.
Report	Supplier	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-041727	QSC	QSC-2602-E9474	Janoshik	2026-Q3	98.88	6.62	105.3	Supplier-supplied	1	MARGINAL
AX-2026-041728	QSC	QSC-2602-E9474	VendorInvestigate	2026-Q3	98.42	7.04	—	Buyer-sourced	1	MARGINAL
AX-2026-041734	QSC	QSC-2602-E9474	Medutest	2026-Q3	99.43	7.17	105.5	Supplier-supplied	2	FAIL
AX-2026-043539	BCH	BCH-2607-H7307	Janoshik	2026-Q3	98.12	5.78	100.6	Supplier-supplied	1	MARGINAL
AX-2026-041730	QSC	QSC-2602-E9474	PeptideMeter	2026-Q3	98.79	6.93	95.4	Supplier-supplied	1	MARGINAL
AX-2026-041731	QSC	QSC-2602-E9474	VendorInvestigate	2026-Q3	99.07	7.18	99.6	Buyer-sourced	1	MARGINAL
AX-2026-041725	QSC	QSC-2602-E9474	Medutest	2026-Q3	99.06	7.04	107.3	Supplier-supplied	2	FAIL
AX-2026-043537	BCH	BCH-2607-H7307	Janoshik	2026-Q3	98.45	5.49	103.1	Supplier-supplied	1	MARGINAL

Other recent WXT records in the index.
Report	Compound	Lot	Lab	Quarter	Purity %	Water %	Recovery %	Provenance	Flags	Result
AX-2026-043488	Pramlintide	WXT-2603-D6052	Janoshik	2026-Q3	97.87	4.37	—	Supplier-supplied	1	MARGINAL
AX-2026-043406	Semaglutide	WXT-2604-C4728	Janoshik	2026-Q3	97.24	4.65	—	Supplier-supplied	1	MARGINAL
AX-2026-043421	Sermorelin	WXT-2608-P4867	Janoshik	2026-Q3	98.15	3.09	—	Supplier-supplied	0	PASS
AX-2026-043420	Sermorelin	WXT-2608-P4867	Medutest	2026-Q3	98.62	3.07	96.4	Supplier-supplied	0	PASS
AX-2026-043423	Sermorelin	WXT-2608-P4867	Janoshik	2026-Q3	98.28	3.86	98.5	Buyer-sourced	0	PASS
AX-2026-043401	Semaglutide	WXT-2604-C4728	Medutest	2026-Q3	97.70	4.78	91.5	Supplier-supplied	1	MARGINAL
AX-2026-043400	Semaglutide	WXT-2604-C4728	Nordanalyt	2026-Q3	96.86	4.11	106.4	Laboratory-retained	1	FAIL
AX-2026-043422	Sermorelin	WXT-2608-P4867	Medutest	2026-Q3	98.35	3.59	—	Supplier-supplied	1	MARGINAL